| 1A30 | A:; B: | HIV-1 PROTEASE COMPLEXED WITH A TRIPEPTIDE INHIBITOR |
| 1A8G | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH SDZ283-910 |
| 1A8K | A:; B:; D:; E: | CRYSTALLOGRAPHIC ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEASE WITH AN ANALOG OF THE CONSERVED CA-P2 SUBSTRATE: INTERACTIONS WITH FREQUENTLY OCCURRING GLUTAMIC ACID RESIDUE AT P2' POSITION OF SUBSTRATES |
| 1A94 | A:; B:; D:; E: | STRUCTURAL BASIS FOR SPECIFICITY OF RETROVIRAL PROTEASES |
| 1A9M | A:; B: | G48H MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH A PEPTIDIC INHIBITOR U-89360E |
| 1AAQ | A:; B: | HYDROXYETHYLENE ISOSTERE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE: STRUCTURE-ACTIVITY ANALYSIS USING ENZYME KINETICS, X-RAY CRYSTALLOGRAPHY, AND INFECTED T-CELL ASSAYS |
| 1AID | A:; B: | STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN |
| 1AJV | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC SULFAMIDE INHIBITOR AHA006 |
| 1AJX | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC UREA INHIBITOR AHA001 |
| 1AXA | A:; B: | ACTIVE-SITE MOBILITY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AS DEMONSTRATED BY CRYSTAL STRUCTURE OF A28S MUTANT |
| 1B6J | A:; B: | HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 1 |
| 1B6K | A:; B: | HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 5 |
| 1B6L | A:; B: | HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 4 |
| 1B6M | A:; B: | HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 6 |
| 1B6P | A:; B: | HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 7 |
| 1BDL | A:; B: | HIV-1 (2:31-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386 |
| 1BDQ | A:; B: | HIV-1 (2:31-37, 47, 82) PROTEASE COMPLEXED WITH INHIBITOR SB203386 |
| 1BDR | A:; B: | HIV-1 (2: 31, 33-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386 |
| 1BV7 | A:; B: | COUNTERACTING HIV-1 PROTEASE DRUG RESISTANCE: STRUCTURAL ANALYSIS OF MUTANT PROTEASES COMPLEXED WITH XV638 AND SD146, CYCLIC UREA AMIDES WITH BROAD SPECIFICITIES |
| 1BV9 | A:; B: | HIV-1 PROTEASE (I84V) COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS |
| 1BVE | A:; B: | HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR, 28 STRUCTURES |
| 1BVG | A:; B: | HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR MINIMIZED AVERAGE STRUCTURE |
| 1BWA | A:; B: | HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS |
| 1BWB | A:; B: | HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH SD146 OF DUPONT PHARMACEUTICALS |
| 1C6X | A:; B: | ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. |
| 1C6Y | A:; B: | ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. |
| 1C6Z | A:; B: | ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. |
| 1C70 | A:; B: | ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. |
| 1CPI | A:; B: | REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF PEPTIDES. DESIGN OF HYDROLYTICALLY STABLE CYCLIC PEPTIDOMIMETIC INHIBITORS OF HIV-1 PROTEASE |
| 1D4H | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA435 |
| 1D4I | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA425 |
| 1D4J | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSL370 |
| 1D4K | A:; B: | HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR |
| 1D4L | A:; B: | HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR |
| 1D4S | A:; B: | HIV-1 PROTEASE V82F/I84V DOUBLE MUTANT/TIPRANAVIR COMPLEX |
| 1D4Y | A:; B: | HIV-1 PROTEASE TRIPLE MUTANT/TIPRANAVIR COMPLEX |
| 1DAZ | C:; D: | STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE |
| 1DIF | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A DIFLUOROKETONE CONTAINING INHIBITOR A79285 |
| 1DMP | A:; B: | STRUCTURE OF HIV-1 PROTEASE COMPLEX |
| 1DW6 | C:; D: | STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE |
| 1EBK | C:; D:; E:; F: | STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE |
| 1EBW | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA322 |
| 1EBY | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA369 |
| 1EBZ | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA388 |
| 1EC0 | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA403 |
| 1EC1 | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA409 |
| 1EC2 | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA428 |
| 1EC3 | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSA367 |
| 1F7A | A:; B: | HOW DOES A SYMMETRIC DIMER RECOGNIZE AN ASYMMETRIC SUBSTRATE? A SUBSTRATE COMPLEX OF HIV-1 PROTEASE. |
| 1FB7 | A: | CRYSTAL STRUCTURE OF AN IN VIVO HIV-1 PROTEASE MUTANT IN COMPLEX WITH SAQUINAVIR: INSIGHTS INTO THE MECHANISMS OF DRUG RESISTANCE |
| 1FEJ | C:; D: | STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES |
| 1FF0 | C:; D: | STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES. |
| 1FFF | C:; D: | STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE : HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES. |
| 1FFI | C:; D: | STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES |
| 1FG6 | C:; D: | STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES |
| 1FG8 | C:; D: | STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES |
| 1FGC | C:; D: | STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES |
| 1FQX | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX OF HIV-1 PROTEASE WITH A PEPTIDOMIMETIC INHIBITOR |
| 1G2K | A:; B: | HIV-1 PROTEASE WITH CYCLIC SULFAMIDE INHIBITOR, AHA047 |
| 1G35 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR, AHA024 |
| 1G6L | A:1-99; A:1001-1099 | 1.9A CRYSTAL STRUCTURE OF TETHERED HIV-1 PROTEASE |
| 1GNM | A:; B: | HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASP (V82D) COMPLEXED WITH U89360E (INHIBITOR) |
| 1GNN | A:; B: | HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASN (V82N) COMPLEXED WITH U89360E (INHIBITOR) |
| 1GNO | A:; B: | HIV-1 PROTEASE (WILD TYPE) COMPLEXED WITH U89360E (INHIBITOR) |
| 1HBV | A:; B: | A CHECK ON RATIONAL DRUG DESIGN. CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A NOVEL GAMMA-TURN MIMETIC |
| 1HEF | E: | THE CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN TWO DISTINCT ORIENTATIONS |
| 1HEG | E: | THE CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN TWO DISTINCT ORIENTATIONS |
| 1HHP | A: | THE THREE-DIMENSIONAL STRUCTURE OF THE ASPARTYL PROTEASE FROM THE HIV-1 ISOLATE BRU |
| 1HIH | A:; B: | COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR |
| 1HIV | A:; B: | CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A DIHYDROETHYLENE-CONTAINING INHIBITOR: COMPARISONS WITH MOLECULAR MODELING |
| 1HOS | A:; B: | INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE BY A C2-SYMMETRIC PHOSPHINATE SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS |
| 1HPO | A:; B: | HIV-1 PROTEASE TRIPLE MUTANT/U103265 COMPLEX |
| 1HPS | A:; B: | RATIONAL DESIGN, SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS OF A HYDROXYETHYLENE-BASED HIV-1 PROTEASE INHIBITOR CONTAINING A HETEROCYCLIC P1'-P2' AMIDE BOND ISOSTERE |
| 1HPV | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME |
| 1HPX | A:; B: | HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR KNI-272 |
| 1HSG | A:; B: | CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES |
| 1HSH | A:; B:; C:; D: | CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES |
| 1HTE | A:; B: | X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE |
| 1HTF | A:; B: | X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE |
| 1HTG | A:; B: | X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE |
| 1HVC | A:1B-99B; A:1A-99A | CRYSTAL STRUCTURE OF A TETHERED DIMER OF HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR |
| 1HVH | A:; B: | NONPEPTIDE CYCLIC CYANOGUANIDINES AS HIV PROTEASE INHIBITORS |
| 1HVI | A:; B: | INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE |
| 1HVJ | A:; B: | INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE |
| 1HVK | A:; B: | INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE |
| 1HVL | A:; B: | INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE |
| 1HVR | A:; B: | RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS |
| 1HVS | A:; B: | STRUCTURAL BASIS OF DRUG RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEASE: BACKBONE FLEXIBILITY AND SUBSITE REPACKING |
| 1HWR | A:; B: | MOLECULAR RECOGNITION OF CYCLIC UREA HIV PROTEASE INHIBITORS |
| 1HXB | A:; B: | HIV-1 PROTEINASE COMPLEXED WITH RO 31-8959 |
| 1HXW | A:; B: | HIV-1 PROTEASE DIMER COMPLEXED WITH A-84538 |
| 1IIQ | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR |
| 1IZH | A:; B: | INHIBITOR OF HIV PROTEASE WITH UNUSUAL BINDING MODE POTENTLY INHIBITING MULTI-RESISTANT PROTEASE MUTANTS |
| 1IZI | A:; B: | INHIBITOR OF HIV PROTEASE WITH UNUSUAL BINDING MODE POTENTLY INHIBITING MULTI-RESISTANT PROTEASE MUTANTS |
| 1K1T | A:; B: | COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE |
| 1K1U | A:; B: | COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE |
| 1K2B | A:; B: | COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE |
| 1K2C | A:; B: | COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE |
| 1K6C | A:; B: | LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE |
| 1K6P | A:; B: | LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE |
| 1K6T | A:; B: | LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE |
| 1K6V | A:; B: | LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE |
| 1KJ4 | A:; B:; C:; D: | SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES |
| 1KJ7 | A:; B: | SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES |
| 1KJF | A:; B: | SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES |
| 1KJG | A:; B: | SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES |
| 1KJH | A:; B: | SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES |
| 1KZK | A:; B: | JE-2147-HIV PROTEASE COMPLEX |
| 1LV1 | A:1-99; A:1001-1099 | CRYSTAL STRUCTURE ANALYSIS OF THE NON-ACTIVE SITE MUTANT OF TETHERED HIV-1 PROTEASE TO 2.1A RESOLUTION |
| 1LZQ | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH AN ETHYLENAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[CH2CH2NH]-PHE-GLU-PHE-NH2 |
| 1M0B | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH AN ETHYLENEAMINE INHIBITOR |
| 1MER | A:; B: | HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP450 |
| 1MES | A:; B: | HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP323 |
| 1MET | A:; B: | HIV-1 MUTANT (V82F) PROTEASE COMPLEXED WITH DMP323 |
| 1MEU | A:; B: | HIV-1 MUTANT (V82F, I84V) PROTEASE COMPLEXED WITH DMP323 |
| 1MRW | A:; B: | STRUCTURE OF HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-577 |
| 1MRX | A:; B: | STRUCTURE OF HIV PROTEASE (MUTANT Q7K L33I L63I V82F I84V ) COMPLEXED WITH KNI-577 |
| 1MSM | A:; B: | THE HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-764 (AN INHIBITOR) |
| 1MSN | A:; B: | THE HIV PROTEASE (MUTANT Q7K L33I L63I V82F I84V) COMPLEXED WITH KNI-764 (AN INHIBITOR) |
| 1MT7 | A:; B: | VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY |
| 1MT8 | A:; B: | VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY |
| 1MT9 | A:; B: | VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY |
| 1MTB | A:; B: | VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY |
| 1MTR | A:; B: | HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL PEPTIDOMIMETIC INHIBITOR |
| 1MUI | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LOPINAVIR. |
| 1N49 | A:; B:; C:; D: | VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER ANTI-VIRAL THERAPY |
| 1NH0 | A:; B: | 1.03 A STRUCTURE OF HIV-1 PROTEASE: INHIBITOR BINDING INSIDE AND OUTSIDE THE ACTIVE SITE |
| 1NPA | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE-HUP |
| 1NPV | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LDC271 |
| 1NPW | A:; B: | CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH LGZ479 |
| 1ODW | A:; B: | NATIVE HIV-1 PROTEINASE |
| 1ODX | A:; B: | HIV-1 PROTEINASE MUTANT A71T, V82A |
| 1ODY | A:; B: | HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130 |
| 1OHR | A:; B: | VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE |
| 1PRO | A:; B: | HIV-1 PROTEASE DIMER COMPLEXED WITH A-98881 |
| 1Q9P | A: | SOLUTION STRUCTURE OF THE MATURE HIV-1 PROTEASE MONOMER |
| 1QBR | A:; B: | HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY |
| 1QBS | A:; B: | HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY |
| 1QBT | A:; B: | HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY |
| 1QBU | A:; B: | HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY |
| 1RL8 | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX OF RESISTANT STRAIN OF HIV-1 PROTEASE(V82A MUTANT) WITH RITONAVIR |
| 1RPI | A:; B: | CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY |
| 1RQ9 | A:; B: | CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY |
| 1RV7 | A:; B: | CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY |
| 1SBG | A:; B: | AN ORALLY-BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE BOND REPLACEMENT. CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS |
| 1SDT | A:; B: | CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE. |
| 1SDU | A:; B: | CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE. |
| 1SDV | A:; B: | CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE. |
| 1SGU | A:; B: | COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE |
| 1SH9 | A:; B: | COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE |
| 1SP5 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A PRODUCT OF AUTOPROTEOLYSIS |
| 1T3R | A:; B: | HIV PROTEASE WILD-TYPE IN COMPLEX WITH TMC114 INHIBITOR |
| 1T7I | A:; B: | THE STRUCTURAL AND THERMODYNAMIC BASIS FOR THE BINDING OF TMC114, A NEXT-GENERATION HIV-1 PROTEASE INHIBITOR. |
| 1T7J | A:; B: | CRYSTAL STRUCTURE OF INHIBITOR AMPRENAVIR IN COMPLEX WITH A MULTI-DRUG RESISTANT VARIANT OF HIV-1 PROTEASE (L63P/V82T/I84V) |
| 1T7K | A:; B: | CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH ARYLSULFONAMIDE AZACYCLIC UREA |
| 1TCX | A:; B: | HIV TRIPLE MUTANT PROTEASE COMPLEXED WITH INHIBITOR SB203386 |
| 1TSQ | A:1-99; B:1-99 | CRYSTAL STRUCTURE OF AP2V SUBSTRATE VARIANT OF NC-P1 DECAMER PEPTIDE IN COMPLEX WITH V82A/D25N HIV-1 PROTEASE MUTANT |
| 1TSU | A:1-99; B:1-99 | CRYSTAL STRUCTURE OF DECAMER NCP1 SUBSTRATE PEPTIDE IN COMPLEX WITH WILD-TYPE D25N HIV-1 PROTEASE VARIANT |
| 1TW7 | A:; B: | WIDE OPEN 1.3A STRUCTURE OF A MULTI-DRUG RESISTANT HIV-1 PROTEASE REPRESENTS A NOVEL DRUG TARGET |
| 1U8G | A:; B: | CRYSTAL STRUCTURE OF A HIV-1 PROTEASE IN COMPLEX WITH PEPTIDOMIMETIC INHIBITOR KI2-PHE-GLU-GLU-NH2 |
| 1UPJ | A: | HIV-1 PROTEASE COMPLEX WITH U095438 [3-[1-(4-BROMOPHENYL) ISOBUTYL]-4-HYDROXYCOUMARIN |
| 1VIJ | A:; B: | HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 HEXAGONAL FORM |
| 1VIK | A:; B: | HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 ORTHORHOMBIC FORM |
| 1W5V | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR |
| 1W5W | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR |
| 1W5X | A: | HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR |
| 1W5Y | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR |
| 1WBK | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH ASYMMETRIC INHIBITOR, BEA568 |
| 1WBM | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH SYMMETRIC INHIBITOR, BEA450 |
| 1XL2 | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH PYRROLIDINMETHANAMINE |
| 1XL5 | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH AMIDHYROXYSULFONE |
| 1YTG | A:; B: | SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT |
| 1YTH | A:; B: | SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT |
| 1Z1H | A:1-99; B:101-199 | HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 3 |
| 1Z1R | A:1-99; B:101-199 | HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 2 |
| 1ZBG | A:; B: | CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2 |
| 1ZJ7 | A: | CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH)CH2NH]-PHE-GLU-PHE-NH2 |
| 1ZLF | A:; B: | CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR |
| 1ZP8 | A: | HIV PROTEASE WITH INHIBITOR AB-2 |
| 1ZPA | A: | HIV PROTEASE WITH SCRIPPS AB-3 INHIBITOR |
| 1ZPK | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2 |
| 1ZSF | A:; B: | CRYSTAL STRUCTURE OF COMPLEX OF A HYDROXYETHYLAMINE INHIBITOR WITH HIV-1 PROTEASE AT 2.0A RESOLUTION |
| 1ZSR | A:; B: | CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE (BRU ISOLATE) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH) CH2NH]-PHE-GLU-PHE-NH2 |
| 1ZTZ | A:; B: | CRYSTAL STRUCTURE OF HIV PROTEASE- METALLACARBORANE COMPLEX |
| 2A1E | A:; B: | HIGH RESOLUTION STRUCTURE OF HIV-1 PR WITH TS-126 |
| 2A4F | A:; B: | SYNTHESIS AND ACTIVITY OF N-AXYL AZACYCLIC UREA HIV-1 PROTEASE INHIBITORS WITH HIGH POTENCY AGAINST MULTIPLE DRUG RESISTANT VIRAL STRAINS. |
| 2AID | A:; B: | STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN |
| 2AOF | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A SUBSTRATE ANALOG P1-P6 |
| 2AQU | A:; B: | STRUCTURE OF HIV-1 PROTEASE BOUND TO ATAZANAVIR |
| 2AVM | A:; B: | KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S |
| 2AVO | A:; B: | KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S |
| 2AVS | A:; B: | KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S |
| 2AVV | A:; B:; D:; E: | KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S |
| 2AZ8 | A: | HIV-1 PROTEASE NL4-3 IN COMPLEX WITH INHIBITOR, TL-3 |
| 2AZ9 | A: | HIV-1 PROTEASE NL4-3 1X MUTANT |
| 2AZB | A: | HIV-1 PROTEASE NL4-3 3X MUTANT IN COMPLEX WITH INHIBITOR, TL-3 |
| 2AZC | A:; B: | HIV-1 PROTEASE NL4-3 6X MUTANT |
| 2BB9 | A:; B: | STRUCTURE OF HIV1 PROTEASE AND AKC4P_133A COMPLEX. |
| 2BBB | A:; B: | STRUCTURE OF HIV1 PROTEASE AND HH1_173_3A COMPLEX. |
| 2BPV | A:; B: | HIV-1 PROTEASE-INHIBITOR COMPLEX |
| 2BPW | A:; B: | HIV-1 PROTEASE-INHIBITOR COMPLEX |
| 2BPX | A:; B: | HIV-1 PROTEASE-INHIBITOR COMPLEX |
| 2BPY | A:; B: | HIV-1 PROTEASE-INHIBITOR COMPLEX |
| 2BPZ | A:; B: | HIV-1 PROTEASE-INHIBITOR COMPLEX |
| 2BQV | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR AHA455 |
| 2CEJ | A:; B: | P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD |
| 2CEM | A:; B: | P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD |
| 2CEN | A:; B: | P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD |
| 2F80 | A:; B: | HIV-1 PROTEASE MUTANT D30N COMPLEXED WITH INHIBITOR TMC114 |
| 2F81 | A:; B: | HIV-1 PROTEASE MUTANT L90M COMPLEXED WITH INHIBITOR TMC114 |
| 2F8G | A:; B: | HIV-1 PROTEASE MUTANT I50V COMPLEXED WITH INHIBITOR TMC114 |
| 2FDE | A:; B: | WILD TYPE HIV PROTEASE BOUND WITH GW0385 |
| 2FGU | A:; B: | X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE T80S VARIANT IN COMPLEX WITH THE INHIBITOR SAQUINAVIR USED TO EXPLORE THE ROLE OF INVARIANT THR80 IN HIV-1 PROTEASE STRUCTURE, FUNCTION, AND VIRAL INFECTIVITY. |
| 2FGV | A:; B: | X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE T80N VARIANT IN COMPLEX WITH THE INHIBITOR SAQUINAVIR USED TO EXPLORE THE ROLE OF INVARIANT THR80 IN HIV-1 PROTEASE STRUCTURE, FUNCTION, AND VIRAL INFECTIVITY. |
| 2FNS | A:; B: | CRYSTAL STRUCTURE OF WILD-TYPE INACTIVE (D25N) HIV-1 PROTEASE COMPLEXED WITH WILD-TYPE HIV-1 NC-P1 SUBSTRATE. |
| 2FNT | A:; B: | CRYSTAL STRUCTURE OF A DRUG-RESISTANT (V82A) INACTIVE (D25N) HIV-1 PROTEASE COMPLEXED WITH AP2V VARIANT OF HIV-1 NC-P1 SUBSTRATE. |
| 2FXD | A:; B: | X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE IRM MUTANT COMPLEXED WITH ATAZANAVIR (BMS-232632) |
| 2FXE | A:; B: | X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE CRM MUTANT COMPLEXED WITH ATAZANAVIR (BMS-232632) |
| 2HB3 | A:; B: | WILD-TYPE HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR GRL06579 |
| 2HB4 | A: | STRUCTURE OF HIV PROTEASE NL4-3 IN AN UNLIGANDED STATE |
| 2HS1 | A:; B: | ULTRA-HIGH RESOLUTION X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE V32I MUTANT WITH TMC114 (DARUNAVIR) INHIBITOR |
| 2HS2 | A:; B: | CRYSTAL STRUCTURE OF M46L MUTANT OF HIV-1 PROTEASE COMPLEXED WITH TMC114 (DARUNAVIR) |
| 2HVP | A: | THREE-DIMENSIONAL STRUCTURE OF ASPARTYL PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS HIV-1 |
| 2I0A | A:; B: | CRYSTAL STRUCTURE OF KB-19 COMPLEXED WITH WILD TYPE HIV-1 PROTEASE |
| 2I0D | A:; B: | CRYSTAL STRUCTURE OF AD-81 COMPLEXED WITH WILD TYPE HIV-1 PROTEASE |
| 2I4D | A:; B: | CRYSTAL STRUCTURE OF WT HIV-1 PROTEASE WITH GS-8373 |
| 2I4U | A:; B: | HIV-1 PROTEASE WITH TMC-126 |
| 2I4V | A:; B: | HIV-1 PROTEASE I84V, L90M WITH TMC126 |
| 2I4W | A:; B: | HIV-1 PROTEASE WT WITH GS-8374 |
| 2I4X | A:; B: | HIV-1 PROTEASE I84V, L90M WITH GS-8374 |
| 2IDW | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017) |
| 2IEN | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017) |
| 2IEO | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017) |
| 2NMY | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR |
| 2NMZ | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR |
| 2NNK | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR |
| 2NNP | A:; B: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR |
| 2NPH | A:; B: | CRYSTAL STRUCTURE OF HIV1 PROTEASE IN SITU PRODUCT COMPLEX |
| 2O4K | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH ATAZANAVIR |
| 2O4L | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, I50V) IN COMPLEX WITH TIPRANAVIR |
| 2O4N | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (TRM MUTANT) IN COMPLEX WITH TIPRANAVIR |
| 2O4P | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH TIPRANAVIR |
| 2O4S | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH LOPINAVIR |
| 2P3A | A:; B: | CRYSTAL STRUCTURE OF THE MULTI-DRUG RESISTANT MUTANT SUBTYPE B HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR |
| 2P3B | A:; B: | CRYSTAL STRUCTURE OF THE SUBTYPE B WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR |
| 2P3C | A:; B: | CRYSTAL STRUCTURE OF THE SUBTYPE F WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR |
| 2PC0 | A: | APO WILD-TYPE HIV PROTEASE IN THE OPEN CONFORMATION |
| 2PK5 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I ) IN COMPLEX WITH KNI-10075 |
| 2PK6 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10033 |
| 2PQZ | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A PYRROLIDINE-BASED INHIBITOR |
| 2PSU | A:; B: | CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-AD37 |
| 2PSV | A:; B: | CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-KB45 |
| 2PWC | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A AMINO DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2PWR | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2PYM | A:; B: | HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR |
| 2PYN | A:; B: | HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR |
| 2Q3K | A:; B: | CRYSTAL STRUCTURE OF LYSINE SULFONAMIDE INHIBITOR REVEALS THE DISPLACEMENT OF THE CONSERVED FLAP WATER MOLECULE IN HIV-1 PROTEASE |
| 2Q54 | A:; B: | CRYSTAL STRUCTURE OF KB73 BOUND TO HIV-1 PROTEASE |
| 2Q55 | A:; B: | CRYSTAL STRUCTURE OF KK44 BOUND TO HIV-1 PROTEASE |
| 2Q5K | A:; B: | CRYSTAL STRUCTURE OF LOPINAVIR BOUND TO WILD TYPE HIV-1 PROTEASE |
| 2Q63 | A:; B: | HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR |
| 2Q64 | A:; B: | HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR |
| 2QCI | A:; B: | HIV-1 PROTEASE MUTANT D30N WITH POTENT ANTIVIRAL INHIBITOR GRL-98065 |
| 2QD7 | A:; B: | HIV-1 PROTEASE MUTANT V82A WITH POTENT ANTIVIRAL INHIBITOR GRL-98065 |
| 2QD8 | A:; B: | HIV-1 PROTEASE MUTANT I84V WITH POTENT ANTIVIRAL INHIBITOR GRL-98065 |
| 2QHC | A:; B: | THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR |
| 2QHY | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QHZ | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC87 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QI0 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK80 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QI1 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK81 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QI3 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD94 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QI4 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD93 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QI5 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KC08 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QI6 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KB98 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QI7 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 2QNN | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A MULTIPLE DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2QNP | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A IODO DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2QNQ | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A CHLORO DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2R38 | A:; B: | I84V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2R3T | A:; B: | I50V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2R3W | A:; B: | I84V HIV-1 PROTEASE IN COMPLEX WITH A AMINO DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2R43 | A:; B: | I50V HIV-1 PROTEASE IN COMPLEX WITH AN AMINO DECORATED PYRROLIDINE-BASED INHIBITOR |
| 2R5P | A:; B:; C:; D: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 SUBTYPE C PROTEASE COMPLEXED WITH INDINAVIR |
| 2R5Q | A:; B:; C:; D: | CRYSTAL STRUCTURE ANALYSIS OF HIV-1 SUBTYPE C PROTEASE COMPLEXED WITH NELFINAVIR |
| 2RKF | A:; B: | HIV-1 PR RESISTANT MUTANT + LPV |
| 2RKG | A:; B: | HIV-1 PR RESISTANT MUTANT + LPV |
| 2UPJ | A:; B: | HIV-1 PROTEASE COMPLEX WITH U100313 ([3-[[3-[CYCLOPROPYL [4-HYDROXY-2OXO-6-[1-(PHENYLMETHYL)PROPYL]-2H-PYRAN-3-YL] METHYL]PHENYL]AMINO]-3-OXO-PROPYL]CARBAMIC ACID TERT-BUTYL ESTER) |
| 2UXZ | A:; B: | TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC |
| 2UY0 | A:; B: | TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC |
| 2WHH | A:1-99; A:1001-1099 | HIV-1 PROTEASE TETHERED DIMER Q-PRODUCT COMPLEX ALONG WITH NUCLEOPHILIC WATER MOLECULE |
| 2Z4O | A:; B: | WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-98065 |
| 2Z54 | A:; B: | THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR |
| 2ZGA | A: | HIV-1 PROTEASE IN COMPLEX WITH A DIMETHYLALLYL DECORATED PYRROLIDINE BASED INHIBITOR (HEXAGONAL SPACE GROUP) |
| 2ZYE | A:; B: | STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR KNI-272 DETERMINED BY NEUTRON CRYSTALLOGRAPHY |
| 3A2O | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH KNI-1689 |
| 3AID | A:; B: | A NEW CLASS OF HIV-1 PROTEASE INHIBITOR: THE CRYSTALLOGRAPHIC STRUCTURE, INHIBITION AND CHEMICAL SYNTHESIS OF AN AMINIMIDE PEPTIDE ISOSTERE |
| 3B7V | A:; B: | HIV-1 PROTEASE COMPLEXED WITH GEM-DIOL-AMINE TETRAHEDRAL INTERMEDIATE NLLTQI |
| 3B80 | A:; B: | HIV-1 PROTEASE MUTANT I54V COMPLEXED WITH GEM-DIOL-AMINE INTERMEDIATE NLLTQI |
| 3BC4 | A: | I84V HIV-1 PROTEASE IN COMPLEX WITH A PYRROLIDINE DIESTER |
| 3BGB | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A ISOBUTYL DECORATED OLIGOAMINE |
| 3BGC | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A BENZYL DECORATED OLIGOAMINE |
| 3BVA | A:; B: | CYSTAL STRUCTURE OF HIV-1 ACTIVE SITE MUTANT D25N AND P2-NC ANALOG INHIBITOR |
| 3BVB | A:; B: | CYSTAL STRUCTURE OF HIV-1 ACTIVE SITE MUTANT D25N AND INHIBITOR DARUNAVIR |
| 3CKT | A:; B: | HIV-1 PROTEASE IN COMPLEX WITH A DIMETHYLALLYL DECORATED PYRROLIDINE BASED INHIBITOR (ORTHOROMBIC SPACE GROUP) |
| 3CYW | A:; B: | EFFECT OF FLAP MUTATIONS ON STRUCTURE OF HIV-1 PROTEASE AND INHIBITION BY SAQUINAVIR AND DARUNAVIR |
| 3CYX | A:; B: | CRYSTAL STRUCTURE OF HIV-1 MUTANT I50V AND INHIBITOR SAQUINAVIRA |
| 3D1X | A:; B: | CRYSTAL STRUCTURE OF HIV-1 MUTANT I54M AND INHIBITOR SAQUINAVIR |
| 3D1Y | A:; B: | CRYSTAL STRUCTURE OF HIV-1 MUTANT I54V AND INHIBITOR SAQUINA |
| 3D1Z | A:; B: | CRYSTAL STRUCTURE OF HIV-1 MUTANT I54M AND INHIBITOR DARUNAVIR |
| 3D20 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 MUTANT I54V AND INHIBITOR DARUNAVIA |
| 3DJK | A:; B: | WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-0255A |
| 3DK1 | A:; B: | WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-0105A |
| 3FX5 | A:; B: | STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR KNI-272 DETERMINED BY HIGH RESOLUTION X-RAY CRYSTALLOGRAPHY |
| 3GGA | A:; B:; C:; D:; G:; H: | HIV PROTEASE INHIBITORS WITH PSEUDO-SYMMETRIC CORES |
| 3GGX | A:; B:; C:; D:; E:; F:; G:; H: | HIV PROTEASE, PSEUDO-SYMMETRIC INHIBITORS |
| 3GI4 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, KB60 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 3GI5 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, KB62 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 3GI6 | A:; B: | CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, AD78 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE |
| 3HVP | A: | CONSERVED FOLDING IN RETROVIRAL PROTEASES. CRYSTAL STRUCTURE OF A SYNTHETIC HIV-1 PROTEASE |
| 3I7E | A:; B: | CO-CRYSTAL STRUCTURE OF HIV-1 PROTEASE BOUND TO A MUTANT RESISTANT INHIBITOR UIC-98038 |
| 3I8W | A: | CRYSTAL STRUCTURE OF A METALLACARBORANE INHIBITOR BOUND TO HIV PROTEASE |
| 3K4V | A:; B:; C:; D: | NEW CRYSTAL FORM OF HIV-1 PROTEASE/SAQUINAVIR STRUCTURE REVEALS CARBAMYLATION OF N-TERMINAL PROLINE |
| 3KDB | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10006 |
| 3KDC | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10074 |
| 3KDD | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10265 |
| 3KF0 | A:; B: | HIV PROTEASE WITH FRAGMENT 4D9 BOUND |
| 3KFN | A:; B: | HIV PROTEASE (PR) WITH INHIBITOR TL-3 AND FRAGMENT HIT 4D9 BY SOAKING |
| 3KFP | A: | HIV PROTEASE (PR) WITH INHIBITOR TL-3 BOUND, AND DMSOS IN EXO SITE |
| 3KFR | A:; B: | HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 1F1 IN THE OUTSIDE/TOP OF FLAP |
| 3KFS | A:; B: | HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 2F4 IN THE OUTSIDE/TOP OF FLAP |
| 3KT2 | A:1-99; A:1001-1099 | CRYSTAL STRUCTURE OF N88D MUTANT HIV-1 PROTEASE |
| 3KT5 | A:1-99; A:1001-1099 | CRYSTAL STRUCTURE OF N88S MUTANT HIV-1 PROTEASE |
| 3LZS | A:; B: | CRYSTAL STRUCTURE OF HIV-1 CRF01_AE PROTEASE IN COMPLEX WITH DARUNAVIR |
| 3LZU | A:; B: | CRYSTAL STRUCTURE OF A NELFINAVIR RESISTANT HIV-1 CRF01_AE PROTEASE VARIANT (N88S) IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR. |
| 3M9F | A:; B: | HIV PROTEASE COMPLEXED WITH COMPOUND 10B |
| 3MWS | A:; B: | CRYSTAL STRUCTURE OF GROUP N HIV-1 PROTEASE |
| 3N3I | A:1-99; A:1001-1099 | CRYSTAL STRUCTURE OF G48V/C95F TETHERED HIV-1 PROTEASE/SAQUINAVIR COMPLEX |
| 3NDT | A:; B:; C:; D: | HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:1 COMPLEX STRUCTURE |
| 3NDU | A:; B:; C:; D: | HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:5 COMPLEX STRUCTURE |
| 3NDW | A:; B: | HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:15 COMPLEX STRUCTURE |
| 3NDX | A:; B: | HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:50 COMPLEX STRUCTURE |
| 3NU3 | A:; B: | WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3NU4 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT V32I WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3NU5 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I50V WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3NU6 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I54M WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3NU9 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I84V WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3NUJ | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I54V WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3NUO | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT L90M WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3OQ7 | A: | CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS |
| 3OQA | A: | CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS |
| 3OQD | A: | CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS |
| 3OU1 | A:; B: | MDR769 HIV-1 PROTEASE COMPLEXED WITH RH/IN HEPTA-PEPTIDE |
| 3OU4 | A:; B: | MDR769 HIV-1 PROTEASE COMPLEXED WITH TF/PR HEPTA-PEPTIDE |
| 3OUA | A:; B: | MDR769 HIV-1 PROTEASE COMPLEXED WITH P1/P6 HEPTA-PEPTIDE |
| 3OUD | A:; B: | MDR769 HIV-1 PROTEASE COMPLEXED WITH CA/P2 HEPTA-PEPTIDE |
| 3OXC | A:; B: | WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG SAQUINAVIR |
| 3OY4 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 L76V PROTEASE IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR. |
| 3PHV | A: | X-RAY ANALYSIS OF HIV-1 PROTEINASE AT 2.7 ANGSTROMS RESOLUTION CONFIRMS STRUCTURAL HOMOLOGY AMONG RETROVIRAL ENZYMES |
| 3PJ6 | A: | CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS |
| 3PSU | A: | HIV-1 PROTEASE IN COMPLEX WITH AN ISOBUTYL DECORATED OLIGOAMINE (SYMMETRIC BINDING MODE) |
| 3PWM | A:; B: | HIV-1 PROTEASE MUTANT L76V WITH DARUNAVIR |
| 3PWR | A:; B: | HIV-1 PROTEASE MUTANT L76V COMPLEXED WITH SAQUINAVIR |
| 3QAA | A:; B: | HIV-1 WILD TYPE PROTEASE WITH A SUBSTITUTED BIS-TETRAHYDROFURAN INHIBITOR, GRL-044-10A |
| 3R0W | A:; B: | CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT HIV-1 PROTEASE IN COMPLEX WITH MECHANISM-BASED ASPARTYL PROTEASE INHIBITORS. |
| 3R0Y | A:; B: | CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT HIV-1 PROTEASE IN COMPLEX WITH MECHANISM-BASED ASPARTYL PROTEASE INHIBITORS |
| 3S43 | A:; B: | HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG AMPRENAVIR |
| 3S53 | A:; B: | HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG DARUNAVIR IN SPACE GROUP P212121 |
| 3S54 | A:; B: | HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG DARUNAVIR IN SPACE GROUP P21212 |
| 3S56 | A:; B: | HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG SAQUINAVIR |
| 3S85 | A:; B:; C:; D:; E:; F:; G:; H:; I:; J:; K:; L: | DISCOVERY OF NEW HIV PROTEASE INHIBITORS WITH POTENTIAL FOR CONVENIENT DOSING AND REDUCED SIDE EFFECTS: A-790742 AND A-792611. |
| 3SO9 | A:; B: | DARUNAVIR IN COMPLEX WITH A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT |
| 3SPK | A:; B: | TIPRANAVIR IN COMPLEX WITH A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT |
| 3ST5 | A:; B: | CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH C3-SUBSTITUTED HEXAHYDROCYCLOPENTAFURANYL URETHANE AS P2-LIGAND, GRL-0489A |
| 3T11 | A:; B: | DIMERIC INHIBITOR OF HIV-1 PROTEASE. |
| 3T3C | A:; B: | STRUCTURE OF HIV PR RESISTANT PATIENT DERIVED MUTANT (COMPRISING 22 MUTATIONS) IN COMPLEX WITH DRV |
| 3TKG | A:; B:; C:; D: | CRYSTAL STRUCTURE OF HIV MODEL PROTEASE PRECURSOR/SAQUINAVIR COMPLEX |
| 3TKW | A:; B: | CRYSTAL STRUCTURE OF HIV PROTEASE MODEL PRECURSOR/DARUNAVIR COMPLEX |
| 3TL9 | A:; B: | CRYSTAL STRUCTURE OF HIV PROTEASE MODEL PRECURSOR/SAQUINAVIR COMPLEX |
| 3TLH | A: | STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITHAN EFFICIENT INHIBITOR OF FIV PR |
| 3U71 | A: | CRYSTAL STRUCTURE ANALYSIS OF SOUTH AFRICAN WILD TYPE HIV-1 SUBTYPE C PROTEASE |
| 3U7S | A:; B: | HIV PR DRUG RESISTANT PATIENT'S VARIANT IN COMPLEX WITH DARUNAVIR |
| 3UCB | A:; B: | CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH DARUNAVIR |
| 3UF3 | A:; B: | CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 |
| 3UFN | A:; B: | CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH SAQUINAVIR |
| 3UHL | A:; B:; C:; D: | CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH P2-NC SUBSTRATE ANALOG |
| 4DFG | A:; B: | CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH CYCLOPENTYLTETRAHYDRO- FURANYL URETHANES AS P2-LIGAND, GRL-0249A |
| 4DQB | A:; B: | CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE IN COMPLEX WITH DRV |
| 4DQC | A:; B: | CRYSTAL STRUCTURE OF (G16C/L38C) HIV-1 PROTEASE IN COMPLEX WITH DRV |
| 4DQE | A:; B: | CRYSTAL STRUCTURE OF (G16C/L38C) HIV-1 PROTEASE IN COMPLEX WITH DRV |
| 4DQF | A:; B: | CRYSTAL STRUCTURE OF (G16A/L38A) HIV-1 PROTEASE IN COMPLEX WITH DRV |
| 4DQG | A:; B: | CRYSTAL STRUCTURE OF APO(G16C/L38C) HIV-1 PROTEASE |
| 4DQH | A:; B: | CRYSTAL STRUCTURE OF (R14C/E65C) HIV-1 PROTEASE IN COMPLEX WITH DRV |
| 4E43 | A:; B: | HIV PROTEASE (PR) DIMER WITH ACETATE IN EXO SITE AND PEPTIDE IN ACTIVE SITE |
| 4EJK | A:; B: | HIV PROTEASE (PR) DIMER IN CLOSED FORM WITH PEPSTATIN IN ACTIVE SITE AND FRAGMENT 1F1-N IN THE OUTSIDE/TOP OF FLAP |
| 4EYR | A:; B: | CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE IN COMPLEX WITH RITONAVIR |
| 4FAF | A:; B: | SUBSTRATE CA/P2 IN COMPLEX WITH A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT |
| 4FE6 | A: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH AN ENAMINO-OXINDOLE INHIBITOR |
| 4FM6 | A:; B: | HIV-1 PROTEASE MUTANT V32I COMPLEXED WITH REACTION INTERMEDIATE |
| 4GZF | A:; B: | MULTI-DRUG RESISTANT HIV-1 PROTEASE 769 VARIANT WITH REDUCED LRF PEPTIDE |
| 4HDB | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS D30N COMPLEXED WITH INHIBITOR GRL-0519 |
| 4HDF | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS V82A COMPLEXED WITH INHIBITOR GRL-0519 |
| 4HDP | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS I50V COMPLEXED WITH INHIBITOR GRL-0519 |
| 4HE9 | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS I54M COMPLEXED WITH INHIBITOR GRL-0519 |
| 4HEG | A:; B: | CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS R8Q COMPLEXED WITH INHIBITOR GRL-0519 |
| 4HVP | A:; B: | STRUCTURE OF COMPLEX OF SYNTHETIC HIV-1 PROTEASE WITH A SUBSTRATE-BASED INHIBITOR AT 2.3 ANGSTROMS RESOLUTION |
| 4I8W | A:; B: | CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH NON-PEPTIDIC INHIBITOR, GRL007 |
| 4I8Z | A:; B: | CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH NON-PEPTIDIC INHIBITOR, GRL008 |
| 4J54 | A:; B: | CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 WITH THE POTENT ANTIVIRAL INHIBITOR GRL-0519A |
| 4J55 | A:; B: | CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 WITH THE POTENT ANTIVIRAL INHIBITOR GRL-02031 |
| 4J5J | A:; B: | CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH AMPRENAVIR |
| 4JEC | A:; B: | JOINT NEUTRON AND X-RAY STRUCTURE OF PER-DEUTERATED HIV-1 PROTEASE IN COMPLEX WITH CLINICAL INHIBITOR AMPRENAVIR |
| 4K4P | A:; B: | TL-3 INHIBITED TRP6ALA HIV PROTEASE |
| 4K4R | A:; B: | TL-3 INHIBITED TRP6ALA HIV PROTEASE WITH 1-BROMO-2-NAPTHOIC ACID BOUND IN EXOSITE |
| 4KB9 | A:; B: | CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH NOVEL TRICYCLIC P2-LIGANDS GRL-0739A |
| 4L1A | A:; B: | CRYSTALLOGRAPHIC STUDY OF MULTI-DRUG RESISTANT HIV-1 PROTEASE LOPINAVIR COMPLEX: MECHANISM OF DRUG RECOGNITION AND RESISTANCE |
| 4MC1 | A:; B: | HIV PROTEASE IN COMPLEX WITH SA526P |
| 4MC2 | A:; B: | HIV PROTEASE IN COMPLEX WITH SA525P |
| 4MC6 | A:; B: | HIV PROTEASE IN COMPLEX WITH SA499 |
| 4MC9 | A:; B: | HIV PROTEASE IN COMPLEX WITH AA74 |
| 4PHV | A:; B: | X-RAY CRYSTAL STRUCTURE OF THE HIV PROTEASE COMPLEX WITH L-700,417, AN INHIBITOR WITH PSEUDO C2 SYMMETRY |
| 5HVP | A:; B: | CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND ACETYL-PEPSTATIN AT 2.0-ANGSTROMS RESOLUTION |
| 7HVP | A:; B: | X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A COMPLEX BETWEEN A SYNTHETIC PROTEASE OF HUMAN IMMUNODEFICIENCY VIRUS 1 AND A SUBSTRATE-BASED HYDROXYETHYLAMINE INHIBITOR |
| 8HVP | A:; B: | STRUCTURE AT 2.5-ANGSTROMS RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE*-BASED INHIBITOR |
| 9HVP | A:; B: | DESIGN, ACTIVITY AND 2.8 ANGSTROMS CRYSTAL STRUCTURE OF A C2 SYMMETRIC INHIBITOR COMPLEXED TO HIV-1 PROTEASE |
)
)